RESEARCH TRIANGLE PARK, N.C. and TUTTLINGEN, Germany, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) (“Asensus Surgical” or “Asensus”), a global leader of innovative digital solutions for the operating room, today announced the closing of the merger (the “Merger”) with the KARL STORZ Group (“KARL STORZ”). The transaction was completed following approval by the Asensus Surgical stockholders. Under the terms of the merger agreement, KARL STORZ Endoscopy-America, Inc., a wholly ...

Asensus Surgical (ASXC) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -40%. A quarter ago, it was expected that this maker of surgical robots and medical instruments would post a loss of $0.05 per share when it actually produced a loss of $0.07, delivering a surprise of -40%.Over the last f ...

财务数据和关键指标变化 - 公司第二季度收入为2.2百万美元,同比增长100%,其中系统收入0.8百万美元、租赁收入0.6百万美元、器械及配件收入0.6百万美元、服务收入0.2百万美元[13] - 第二季度总运营费用为23.1百万美元,同比增加22.2%[14] - 第二季度归属普通股东净亏损为25.7百万美元,每股亏损0.09美元,同比增加24.2%[14] - 第二季度经调整的归属普通股东净亏损为18.1百万美元,每股亏损0.07美元,同比减少10.8%[15][16] 各条业务线数据和关键指标变化 - 公司未具体披露各业务线的数据和指标变化情况[无] 各个市场数据和关键指标变化 - 公司未具体披露各市场的数据和指标变化情况[无] 公司战略和发展方向及行业竞争 - 公司正在与KARL STORZ进行并购,目前正在寻求股东批准[18][20] - 如果并购未获批准,公司将面临20百万美元的债务偿还、交易费用等重大财务压力,可能会申请破产[27][28] - 公司在并购前曾探索过其他合作和收购机会,但未能达成更好的交易[30][31] 管理层对经营环境和未来前景的评论 - 管理层强调如果并购未获批准,公司将面临严重的财务困境,可能会申请破产,这将导致股东收益大幅缩水[27][28][29] - 管理层认为KARL STORZ提出的每股0.35美元的收购价格已经是在目前情况下可以获得的最佳价格[30][31] 其他重要信息 - 公司已经推迟了股东大会的表决时间,希望能够获得更多股东的投票支持[18][19] - 目前已有超过80%的已投票股东支持并购,并得到了ISS和Glass Lewis的推荐[25][26] - 公司鼓励所有股东尽快投票,不管是支持还是反对,都希望每个股东的意见都能被听到[32] 问答环节重要的提问和回答 无

合并协议 - 公司宣布与KARL STORZ Endoscopy-America, Inc.达成合并协议，KARL STORZ将以每股0.35美元的现金收购Asensus Surgical的全部股份[2] - 独立代理顾问公司ISS和Glass Lewis建议股东投票赞成合并提案[3] - 公司鼓励所有股东参与这次关键的合并投票[5][9] - 公司已收到约55%的股份代理投票，其中超过80%赞成合并提案[5] - 如果合并未获批准，公司将寻求申请破产保护以最大化资产价值[7] - 如果合并未获批准，公司将需要筹集超过3亿美元以维持至2027年的运营[6] 财务状况 - 第二季度收入为220万美元[11] - 第二季度净亏损为2570万美元，每股亏损0.09美元[13] - 调整后第二季度净亏损为1810万美元，每股亏损0.07美元[14] - 公司在2024年6月30日拥有约780万美元的现金及现金等价物[15] - 公司总资产为59,086美元，较上年同期增加53.5%[32] - 流动负债总额为39,920美元，较上年同期增加216.2%[30] - 长期负债总额为9,909美元，较上年同期增加12.1%[30] - 净亏损为48,246美元，较上年同期增加12.5%[37] - 调整后净亏损为36,133美元，较上年同期减少14.6%[38] - 每股基本和稀释亏损为0.18美元，与上年同期持平[39] - 调整后每股基本和稀释亏损为0.14美元，较上年同期减少22.2%[40] - 公司获得15,000美元的借款[33] - 公司获得982美元的股票发行收益[33] - 公司获得3,000美元的投资到期收益[33]

合并交易相关 - 公司已与KARL STORZ签署了合并协议,但需获得股东批准才能完成交易[140,215] - 公司正在就合并协议和合并事宜征求股东批准[140] - 公司可能会在合并未获批准的情况下寻求破产保护[215] - 公司正面临两起诉讼,指控合并相关信息披露存在误导或不完整[213] 内部控制和信息技术 - 公司存在内部控制重大缺陷,正在采取补救措施[208,210,212] - 公司将继续加强信息技术控制,包括用户访问管理和培训[212] 财务状况 - 公司2024年上半年海外收入占比88%,主要集中在欧洲市场[207] - 公司2024年上半年外汇波动对收入的影响不大,约300万美元[207] - 公司已向KARL STORZ发行了一笔有担保的承兑票据,用于提供过渡期融资[141,208] 董事和高管交易 - 公司董事和高管在报告期内未采取或终止任何Rule 10b5-1交易安排[217]

RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a global leader of innovative digital solutions for the operating room, today announced that the Company's Special Meeting of Stockholders, scheduled to be held on Wednesday, August 7, 2024 at 10:00 a.m. (Eastern Time), was adjourned to Tuesday, August 20, at 10:00 a.m. (Eastern Time). The Special Meeting will be held virtually. While we have received proxies for approximately 52% of our outstanding shares wi ...

RESEARCH TRIANGLE PARK, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. (“ISS”), became the second advisory firm to recommend that Asensus Surgical stockholders vote “FOR” all proposals relating to the pending merger transaction with KARL STORZ Endoscopy-America, Inc. (“KARL STORZ”). The vote will t ...

RESEARCH TRIANGLE PARK, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a global leader of innovative digital solutions for the operating room, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. ("ISS"), became the second advisory firm to recommend that Asensus Surgical stockholders vote "FOR" all proposals relating to the pending merger transaction with KARL STORZ Endoscopy-America, Inc. ("KARL STORZ"). The vote will take place ...

RESEARCH TRIANGLE PARK, N.C., July 29, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a global leader of innovative digital solutions for the operating room, announced today that a leading independent proxy advisory firm, Glass, Lewis & Co. ("Glass Lewis"), has recommended that Asensus Surgical stockholders vote "FOR" all proposals relating to the pending merger transaction with KARL STORZ Endoscopy-America, Inc. ("KARL STORZ"). The vote will take place at the Company's upcoming Special Meetin ...

RESEARCH TRIANGLE PARK, N.C., July 29, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, announced today that a leading independent proxy advisory firm, Glass, Lewis & Co. (“Glass Lewis”), has recommended that Asensus Surgical stockholders vote “FOR” all proposals relating to the pending merger transaction with KARL STORZ Endoscopy-America, Inc. (“KARL STORZ”). The vote will take place at the Company’s upcoming Spec ...